Cell And Gene Therapy Videos

  1. How CRISPR And LNP Accelerate Therapeutic Innovation Through Analytics 9/2/2025

    CRISPR gene editing and lipid nanoparticle delivery are revolutionizing precision medicine. Discover how optimized LNP systems and advanced analytics accelerate therapeutic development.

  2. Enabling CTA Submission In Record Time: Adenovirus Program Success 8/25/2025

    What does it take to bring an adenovirus-based therapy to the clinic – faster and without compromising quality? Find actionable insights to help improve efficiency and accelerate development timelines.

  3. Donor-To-Dose Solutions For Scalable Cell Therapy Manufacturing 8/21/2025

    From enabling earlier insights through donor characterization to reducing manufacturing variability through cell separation technologies, explore real-world case studies and actionable approaches to scale smarter.

  4. Viralgen Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.

  5. Minaris Advanced Therapies Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, Minaris delivers speed, scalability, and reliability to help therapeutic developers bring cures to patients faster.

  6. Excellos Capacity Update July 2025: Cell & Gene Therapy 7/28/2025

    Excellos leverages its extensive starting material expertise as a key differentiator. Explore how our deep understanding of partner-sourced raw materials, quality control, and supply chain management creates significant value for our clients.

  7. A Concept-To-Commercial Gene Therapy CDMO 7/28/2025

    The Curator™ adherent platform has been used to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.

  8. ReciBioPharm Capacity Update July 2025: Analytical Services 7/28/2025

    ReciBioPharm’s specialized CDMO capabilities include development and manufacture for new biological modalities. Discover the benefits of choosing a CDMO with complete end-to-end services and in-house analytical capabilities.

  9. Alcami Capacity Update July 2025: Analytical Services 7/28/2025

    Alcami’s laboratory services can support many drug substance or drug product modalities, all product phases, and specialty laboratory services, including in-house microbiology, raw materials, and analytical development.

  10. Maximizing Results For Viral Clearance Studies 7/25/2025

    Explore virus strain selection and titer strategies to optimize viral clearance studies, covering regulatory expectations, study design, and execution best practices.